No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?

被引：36

作者：

Braun, Juergen ^{[1
]}

Landewe, Robert B. M. ^{[2
,3
]}

机构：

[1] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany

[2] Amsterdam Rheumatol Ctr, AMC, Amsterdam, Netherlands

[3] Zuyderland Med Ctr, Rheumatol, Heerlen, Netherlands

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷 / 04期

关键词：

DISEASE-ACTIVITY INDEX; ANKYLOSING-SPONDYLITIS;

D O I：

10.1136/annrheumdis-2021-221422

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The three monoclonal antibodies ustekinumab, guselkumab and risankizumab targeting the p 40 or the 19 subunit of interleukin -23 have now been approved for the indication psoriasis and the former two also for psoriatic arthritis (PsA). Ustekinumab and risankizumab have appeared ineffective in randomised controlled trials with patients with axial spondyloarthritis (axSpA), but post-hoc analyses of PsA trials have now suggested that they may improve back pain symptoms potentially induced by axial inflammation based on PsA. Here we argue that, based on the absence of efficacy in axSpA, this is unlikely and more probably due to generic, non-specific effects, which are not adequately covered by the tools developed for the assessment of inflammation in axSpA.

引用

页码：466 / 468

页数：3

共 17 条

[1] Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life [J].

Aydin, Sibel Zehra ;

Kucuksahin, Orhan ;

Kilic, Levent ;

Dogru, Atalay ;

Bayindir, Ozun ;

Ozisler, Cem ;

Omma, Ahmet ;

Tarhan, Emine Figen ;

Erden, Abdulsamet ;

Kimyon, Gezmis ;

Can, Meryem ;

Dalkilic, Ediz ;

Yavuz, Sule ;

Ureyen, Sibel Bakirci ;

Gunal, Esen Kasapoglu ;

Alhussain, Fatima Arslan ;

Akyol, Lutfi ;

Balkarli, Ayse ;

Yilmaz, Sema ;

Cinar, Muhammet ;

Aydin, Muge Tufan ;

Solmaz, Dilek ;

Mercan, Ridvan ;

Erten, Sukran ;

Kalyoncu, Umut .

CLINICAL RHEUMATOLOGY, 2018, 37 (12) :3443-3448

[2] Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study [J].

Baeten, Dominique ;

Ostergaard, Mikkel ;

Wei, James Cheng-Chung ;

Sieper, Joachim ;

Jarvinen, Pentti ;

Tam, Lai-Shan ;

Salvarani, Carlo ;

Kim, Tae-Hwan ;

Solinger, Alan ;

Datsenko, Yakov ;

Pamulapati, Chandrasena ;

Visvanathan, Sudha ;

Hall, David B. ;

Aslanyan, Stella ;

Scholl, Paul ;

Padula, Steven J. .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (09) :1295-1302

[3] Comorbidities, pain and fatigue in psoriatic arthritis, psoriasis and healthy controls: a clinical cohort study [J].

Ballegaard, Christine ;

Skougaard, Marie ;

Guldberg-Moller, Jorgen ;

Nissen, Christoffer, V ;

Amris, Kirstine ;

Jorgensen, Tanja S. ;

Dreyer, Lene ;

Kristensen, Lars E. .

RHEUMATOLOGY, 2021, 60 (07) :3289-3300

[4] Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial [J].

Baraliakos, Xenofon ;

Gossec, Laure ;

Pournara, Effie ;

Jeka, Slawomir ;

Mera-Varela, Antonio ;

D'Angelo, Salvatore ;

Schulz, Barbara ;

Rissler, Michael ;

Nagar, Kriti ;

Perella, Chiara ;

Coates, Laura C. .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (05) :582-590

[5] Clinical manifestations and responsiveness to adalimumab are similar in patients with ankylosing spondylitis with and without concomitant psoriasis [J].

Braun, Juergen ;

Rudwaleit, Martin ;

Kary, Sonja ;

Kron, Martina ;

Wong, Robert L. ;

Kupper, Hartmut .

RHEUMATOLOGY, 2010, 49 (08) :1578-1589

[6] The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status? [J].

Coates, Laura C. ;

Baraliakos, Xenofon ;

Blanco, Francisco J. ;

Alonso Blanco-Morales, Elena ;

Braun, Jurgen ;

Chandran, Vinod ;

Luis Fernandez-Sueiro, Jose ;

FitzGerald, Oliver ;

Gallagher, Phil ;

Gladman, Dafna D. ;

Gubar, Elena ;

Korotaeva, Tatiana ;

Loginova, Elena ;

Lubrano, Ennio ;

Mulero, Juan ;

Pinto-Tasende, Jose ;

Queiro, Ruben ;

Sanz Sanz, Jesus ;

Szentpetery, Agnes ;

Helliwell, Philip S. .

ARTHRITIS CARE & RESEARCH, 2021, 73 (06) :856-860

[7] Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis [J].

Deodhar, Atul ;

Gensler, Lianne S. ;

Sieper, Joachim ;

Clark, Michael ;

Calderon, Cesar ;

Wang, Yuhua ;

Zhou, Yiying ;

Leu, Jocelyn H. ;

Campbell, Kim ;

Sweet, Kristen ;

Harrison, Diane D. ;

Hsia, Elizabeth C. ;

van der Heijde, Desiree .

ARTHRITIS & RHEUMATOLOGY, 2019, 71 (02) :258-270

[8] Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? [J].

Feld, Joy ;

Ye, Justine Yang ;

Chandran, Vinod ;

Inman, Robert D. ;

Haroon, Nigil ;

Cook, Richard J. ;

Gladman, Dafna D. .

RHEUMATOLOGY, 2020, 59 (06) :1340-1346

[9] Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials [J].

Helliwell, Philip S. ;

Gladman, Dafna D. ;

Chakravarty, Soumya D. ;

Kafka, Shelly ;

Karyekar, Chetan S. ;

You, Yin ;

Campbell, Kim ;

Sweet, Kristen ;

Kavanaugh, Arthur ;

Gensler, Lianne S. .

RMD OPEN, 2020, 6 (01)

[10] Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2) [J].

Kavanaugh, Arthur ;

Puig, Lluis ;

Gottlieb, Alice B. ;

Ritchlin, Christopher ;

You, Yin ;

Li, Shu ;

Song, Michael ;

Randazzo, Bruce ;

Rahman, Proton ;

McInnes, Iain B. .

ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (11) :1984-1988

← 1 2 →